权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

MicroRNAs to Understand Cause and Outcome in Breast Cancer

MicroRNA 用于了解乳腺癌的原因和结果

基本信息

批准号：
8856516
负责人：
FRANK J. SLACK
金额：
$ 33.32万
依托单位：
UNIVERSITY OF CALIFORNIA LOS ANGELES
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-09-17 至 2017-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8856516
关键词：
3&apos Untranslated Regions Area BRCA1 gene Binding Binding Sites Biological Markers Biology Breast Breast Cancer Patient Breast Cancer gene Cancer Biology Cell Line Cell Proliferation Cell Survival Cells Cellular biology Cytotoxic agent Data Development Disease Disease-Free Survival ERBB2 gene Estrogens Etiology Event Fatty acid glycerol esters Future Gene Expression Profile Genes Genetic Genetic Polymorphism Goals In Vitro Individual Inherited KRAS2 gene MCF10A cells Maintenance Malignant Neoplasms Mammary Gland Parenchyma Mammary Neoplasms Measures Messenger RNA MicroRNAs Neoadjuvant Therapy Outcome Outcome Measure Pathway interactions Patients Pattern Progesterone RNA Regulation Risk Risk Factors Role Technology Testing Transgenic Mice Transplantation Tumor Biology Variant Woman Xenograft procedure base cancer risk cell transformation cohort demographics gain of function genetic variant in vivo in vivo Model insight interest malignant breast neoplasm mouse model novel personalized medicine prevent receptor receptor expression response therapy outcome treatment response triple helix triple-negative invasive breast carcinoma tumor

项目摘要

DESCRIPTION (provided by applicant): MicroRNAs (miRNAs) are global RNA regulators and important master controllers of the cell survival and proliferation pathways that are critically important in cancer development and tumor maintenance. Recent evidence from our group and others show that miRNA binding site polymorphisms in the 3' untranslated regions (3'UTRs) of mRNAs can strongly impact cancer risk, and that miRNA expression patterns in tumors are important biomarkers of outcome and treatment response. We hypothesize that advances in miRNA understanding can be applied to breast cancer. Breast cancer has 3 main sub-types based on expression of the receptor molecules ER (estrogen), PR (progesterone) and HER2/neu. Breast cancers negative for all of these receptors (triple negative breast cancer [TNBC]) have the worst outcome, and little is known about the etiology and risk factors for this sub-type. We hypothesize that advances in the novel area of miRNA biology can be applied to TNBC to identify novel biomarkers of risk and outcome as well as understand fundamental mechanisms of disease. The overall goal of this proposal is to study miRNA 3'UTR polymorphisms as initiating events in breast cancer, and to define the predictive role of miRNA expression patterns to identify biomarkers of response to therapy and outcome. We will ultimately test our findings that 3'UTR polymorphisms and misregulated miRNAs are key in breast cancer development using in vivo xenograft and transgenic mouse models. By accomplishing these aims we will be able to appropriately risk stratify women for the risk of developing breast cancer, as well as identify biomarkers predicting their response to therapy and ultimate outcome. We expect to gain insight into the fundamental biology behind breast cancer development, and to further identify miRNAs that are new targets in breast cancer response, to make significant strides towards personalized medicine for women.

描述（由申请人提供）：微小RNA（miRNA）是全球RNA调节因子，也是细胞存活和增殖途径的重要主控制因子，在癌症发展和肿瘤维持中至关重要。最近来自我们小组和其他人的证据表明，mRNA的3'非翻译区（3' UTR）中的miRNA结合位点多态性可以强烈影响癌症风险，并且肿瘤中的miRNA表达模式是结果和治疗反应的重要生物标志物。我们假设miRNA理解的进展可以应用于乳腺癌。基于受体分子ER（雌激素）、PR（孕酮）和HER 2/neu的表达，乳腺癌具有3种主要亚型。所有这些受体阴性的乳腺癌（三阴性乳腺癌[TNBC]）具有最差的结果，并且对该亚型的病因学和风险因素知之甚少。我们假设miRNA生物学新领域的进展可以应用于TNBC，以确定风险和结果的新生物标志物，并了解疾病的基本机制。该提案的总体目标是研究miRNA 3 'UTR多态性作为乳腺癌的起始事件，并确定miRNA表达模式的预测作用，以确定对治疗和结果的反应的生物标志物。我们最终将使用体内异种移植和转基因小鼠模型来验证我们的发现，即3 'UTR多态性和失调的miRNA在乳腺癌发展中是关键的。通过实现这些目标，我们将能够适当地对女性患乳腺癌的风险进行风险分层，并确定预测其对治疗反应和最终结果的生物标志物。我们希望能够深入了解乳腺癌发展背后的基本生物学，并进一步确定作为乳腺癌反应新靶点的miRNAs，从而在女性个性化医疗方面取得重大进展。